Clinical trial protocols are often built on a careful balance of scientific rigor, competitive positioning, regulatory precedent, and historical templates. On paper, they can look precise and defensible. In practice, they sometimes describe a patient population that barely exists outside the protocol itself.
This disconnect between protocol assumptions and real-world clinical practice is one of the most persistent drivers of enrollment delays and representativeness gaps. As real-world data becomes more accessible and more actionable, sponsors have an opportunity to narrow that gap before a study ever launches.
The question is simple: are we designing trials for theoretical patients, or for the patients who actually exist?
The Eligibility Trap
Eligibility criteria are meant to protect patient safety, ensure internal validity, and define a clear population for analysis. Over time, however, criteria tend to accumulate. Comorbidity exclusions, prior treatment requirements, washout periods, laboratory thresholds, and age limits are added incrementally, often based on precedent or caution.
Each individual criterion may be reasonable. The combined effect can be dramatic.
When draft eligibility criteria are applied to large real-world datasets such as claims or electronic health records, sponsors often discover that a substantial percentage of patients receiving treatment in routine practice would be excluded from the trial. Common, manageable comorbidities can eliminate large segments of the population. Treatment history requirements may not align with how physicians actually sequence therapies. Washout periods may conflict with the realities of switching behavior in clinical care.
These mismatches are not abstract. They directly affect the size, diversity, and geographic distribution of the recruitable population.
From Assumption to Simulation
Historically, feasibility assessments relied heavily on site surveys and historical enrollment benchmarks. Those inputs remain important, but they are no longer sufficient on their own.
Real-world data enables sponsors to simulate eligibility before protocol lock. By applying draft inclusion and exclusion criteria to longitudinal datasets, teams can estimate how many patients qualify, where they are located, and how frequently they interact with healthcare systems. Pharmacy claims can illuminate treatment patterns and switching timelines. Medical claims can reveal comorbidity prevalence and care pathways. Electronic health records can provide more granular clinical detail.
This type of pressure-testing shifts protocol design from assumption-based to evidence-based.
For example, expanding an upper age limit by a few years or reconsidering the exclusion of a well-controlled chronic condition may meaningfully increase the eligible population without compromising safety. Reducing overly long washout requirements can better align the study with actual clinical transitions between therapies.
When these insights are surfaced early, teams can make informed trade-offs rather than facing recruitment challenges months later.
Representation Starts in Design
Underrepresentation in clinical trials is often framed as a recruitment problem. In many cases, it is a design problem.
If eligibility criteria disproportionately exclude populations with higher comorbidity burden, limited access to specialty care, or different treatment histories, then diversity efforts downstream face structural constraints upstream. Geographic site placement decisions that do not account for where eligible patients actually live further compound the issue.
Real-world demographic and geographic analyses can guide smarter site selection and outreach planning. Mapping patient density and care patterns by region helps identify where recruitment investments are most likely to succeed. Layering demographic insights onto eligibility simulations allows teams to anticipate representation gaps before the first patient is screened.
Designing for representativeness is far more efficient than trying to correct for imbalance after enrollment has begun.
Balancing Rigor and Realism
There is legitimate tension between broadening eligibility and maintaining scientific rigor. Trials must control for confounding variables and ensure patient safety. The goal is not to eliminate thoughtful criteria. The goal is to ensure that each criterion has a clear, defensible purpose grounded in both science and real-world relevance.
Cross-functional review can strengthen this balance. Clinical, regulatory, statistical, operational, and patient engagement leaders each bring different lenses to the conversation. When supported by real-world data simulations, those discussions become more concrete and less speculative.
The outcome is often a protocol that remains scientifically robust while being more aligned with everyday practice.
Designing With the End in Mind
Approved therapies are used in heterogeneous populations, often with comorbidities and treatment histories that differ from the narrow profiles in pivotal trials. Designing studies that better reflect real-world use strengthens external validity and supports more confident clinical decision-making after approval.
It also supports speed. Larger eligible populations, fewer screen failures, and more realistic site placement strategies reduce pressure on recruitment timelines.
As access to real-world data expands and analytic tools become more sophisticated, the barrier to feasibility-informed design continues to shrink. The limiting factor is no longer data availability. It is willingness to interrogate long-standing assumptions.
The future of protocol development belongs to teams that test their designs against reality early and often.
Designing trials for the patients who actually exist is not a compromise. It is a strategic advantage.
Continue the Conversation at SCOPE X
If you are exploring how real-world data and AI can strengthen feasibility, improve representativeness, and reduce enrollment risk, join us at SCOPE X, a dedicated event focused on AI innovation in clinical trials.
SCOPE X brings together sponsors, data leaders, and technology innovators to examine practical strategies for integrating real-world evidence, advanced analytics, and responsible AI into modern trial design and execution.
Learn more at www.scopesummit.com/scopex